Jeff Settleman
Chief Tech/Sci/R&D Officer chez PFIZER, INC.
Profil
Jeff Settleman is currently the Co-Chief Scientific Officer at Pfizer Inc. and a Member of the Scientific Advisory Board at Trillium Therapeutics ULC.
Previously, he worked as the Director of Scientific and Molecular Therapeutics at Massachusetts General Hospital Cancer Center, a Professor at Harvard Medical School, and the Head of Oncology Research at Calico LLC.
Settleman received his undergraduate degree from the University of Pennsylvania and his doctorate from Yale University.
Postes actifs de Jeff Settleman
Sociétés | Poste | Début |
---|---|---|
TRILLIUM THERAPEUTICS | Corporate Officer/Principal | - |
PFIZER, INC. | Chief Tech/Sci/R&D Officer | 01/07/2019 |
Anciens postes connus de Jeff Settleman
Sociétés | Poste | Fin |
---|---|---|
Harvard Medical School | Corporate Officer/Principal | - |
Massachusetts General Hospital Cancer Center
Massachusetts General Hospital Cancer Center Hospital/Nursing ManagementHealth Services Massachusetts General Hospital Cancer Center operates as cancer treatment center. The company was founded by John Warren in 1811 and is headquartered in Boston, MA. | Chief Tech/Sci/R&D Officer | - |
Calico LLC
Calico LLC BiotechnologyHealth Technology Part of Alphabet, Inc., Calico LLC conducts research into the biology of aging. The private company is based in South San Francisco, CA. Arthur D. Levinson has been the CEO of the company since 2013. | Corporate Officer/Principal | - |
Formation de Jeff Settleman
University of Pennsylvania | Undergraduate Degree |
Yale University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
PFIZER, INC. | Health Technology |
Entreprise privées | 3 |
---|---|
Trillium Therapeutics ULC
Trillium Therapeutics ULC BiotechnologyHealth Technology Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada. | Health Technology |
Massachusetts General Hospital Cancer Center
Massachusetts General Hospital Cancer Center Hospital/Nursing ManagementHealth Services Massachusetts General Hospital Cancer Center operates as cancer treatment center. The company was founded by John Warren in 1811 and is headquartered in Boston, MA. | Health Services |
Calico LLC
Calico LLC BiotechnologyHealth Technology Part of Alphabet, Inc., Calico LLC conducts research into the biology of aging. The private company is based in South San Francisco, CA. Arthur D. Levinson has been the CEO of the company since 2013. | Health Technology |